Clinical Trials

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Phase 1 Recruiting

300 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT04205409 2026-05-12

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02879695 2026-04-29

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Phase 1 Active not recruiting

28 enrolled 16 charts

Phase 2 Active not recruiting

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT02275533 2026-04-13

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

82 enrolled 13 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Myeloid, Acute

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Phase 2 Active not recruiting

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

8 enrolled 9 charts

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05255601 2026-02-25

RELATIVITY-069

5 enrolled

Phase 1 Active not recruiting

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

27 enrolled

MyeloidOther hematologic neoplasmThoracic

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02329847 2025-05-25

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

144 enrolled 22 charts

Hematologic Neoplasms

NCT04277442 2025-03-25

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

1 enrolled 8 charts

Leukemia, Myeloid, Acute

NCT02631746 2025-03-14

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

3 enrolled 8 charts

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2/3 Completed

76 enrolled 16 charts

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02532231 2024-10-24

Nivolumab in AML in Remission at High Risk for Relapse

15 enrolled 10 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

7 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

37 enrolled 6 charts

Hodgkin Disease, Hematologic Neoplasms

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03417154 2023-05-26

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

12 enrolled 10 charts

Leukemia, Myeloid, Acute

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

106 enrolled 27 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03121534 2023-02-17

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Phase 2 Terminated

9 enrolled 10 charts

Hematologic Neoplasms

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

30 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

13 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04044209 2022-01-20

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02464657 2021-10-07

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

44 enrolled 12 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03146468 2021-09-23

NIVALLO

Phase 2 Unknown

14 enrolled

Hematologic Neoplasms

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

71 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

LymphoidOther hematologic neoplasmPlasma cell

47 enrolled 10 charts

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Leukemia, Myeloid, Acute

NCT02985554 2020-06-25

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Phase 1 Terminated

3 enrolled